FDA panel recommends limited use of Androxal type drugs
September 18, 2014 at 17:12 PM EDT
A
Food and Drug Administration advisory panel recommended that the agency limit the use
of low testosterone drugs such as Repros Therapeutics Inc.'s (Nasdaq: RPRX)
Androxal. Shares of the biopharmaceutical plunged $2.79 to close at $10.09.
